As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2 billion-Swiss-francs luster to the once high-flying portfolio.

Roche (OTCQX:RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of a certain type of breast cancer with a PIK3CA mutation. The agency ...

Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late last year, although full analysis of the OS has only been completed by ...